Teprotumumab
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research[1].
Product Specifications
CAS Number
[1036734-93-6]
UNSPSC
12352203
Target
IGF-1R; TSH Receptor
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein; Protein Tyrosine Kinase/RTK
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology
Assay Protocol
https://www.medchemexpress.com/teprotumumab.html
Purity
99.46
Solubility
10 mM in DMSO
Smiles
[Teprotumumab]
Molecular Weight
(145.671 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
BCOR, ID (S1122) (BCL-6 Corepressor, BCoR, KIAA1575) (FITC) discontinued
SIGLEC6 (Sialic Acid binding Ig-like Lectin 6, Siglec-6, Obesity-binding Protein 1, OB-BP1, CD33 Antigen-like 1, CDw327, CD327, CD33L, CD33L1, OBBP1) (PE)
SIGLEC6 (Sialic Acid binding Ig-like Lectin 6, Siglec-6, Obesity-binding Protein 1, OB-BP1, CD33 Antigen-like 1, CDw327, CD327, CD33L, CD33L1, OBBP1) (PE)
